Rhonda Patrick· PhD
A single dose of psilocybin substantially diminished depression and anxiety in patients with advanced cancer.
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
A single dose of psilocybin substantially diminished depression and anxiety in patients with advanced cancer.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
And although the design of the study was such, it was a crossover design so people were crossed over between essentially an inactive dose of psilocybin to an active dose or vice-versa. So the strongest conclusion we can make comparing our placebo condition and our active condition is this effect lasted out to five weeks
So, in other words, most people who demonstrated a large therapeutic effect remained having low levels of anxiety or depression out to six months.
but in fact, we followed people out to six months and there was no evidence that there was any significant rate of relapse over that period of time.
I know from Steve, you know, that he’s followed up on people, these are depressed, anxious people with cancer, that those who are still alive two years, later many of them, most of them are still un-depressed and not taking...